Breast cancer recurrence diagnosis suspected on tumor marker rising

Cancer

Volumn 117, Issue 8, 2011, Pages 1621-1629

  Champion, Laurence ^a   Brain, Etienne ^a   Giraudet, Anne Laure ^a   Le Stanc, Elise ^b   Wartski, Myriam ^a   Edeline, Véronique ^a   Madar, Olivier ^a   Bellet, Dominique ^a,c   Pecking, Alain ^a   Alberini, Jean Louis ^a,d  

^a INSTITUT CURIE   (France)

^b FOCH HOSPITAL   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

18FDG PET CT; breast cancer; CA 15 3; CEA; patient management; recurrence; tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MUCIN-1; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 79953768774     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25727     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M., Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 205-249.
2. European Society of Medical Oncology. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. 2007; 18: ii5-ii8.
3. Basuyau J, Blanc-Vincent M, Bidart J, et al. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000. Br J Cancer. 2003; 89: S32-S34. (Pubitemid 37076147)
4. Molina R, Barak V, Van Dalen A, et al. Tumor markers in breast cancerâEuropean Group on tumor markers recommendations. Tumor Biol. 2005; 26: 281-293. (Pubitemid 41619458)
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007: update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5291.
6. Lu W, Schaapveld M, Jansen L, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009; 45: 3000-3007.
7. Lonneux M, Borbath II, Berliere M, Kirkove C, Pauwels S., The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging. 2000; 3: 45-49.
8. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer. 2001; 2: 229-234. (Pubitemid 33085771)
9. Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002; 46: 113-121.
10. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38: 250-256. (Pubitemid 36535030)
11. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW., [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003; 129: 147-153. (Pubitemid 36583695)
12. Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN., [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging. 2004; 31: 179-188. (Pubitemid 38173692)
13. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O., The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006; 107: 2545-2551. (Pubitemid 44845606)
14. Veit-Haibach P, Antoch G, Beyer T, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007; 80: 508-515. (Pubitemid 47343078)
15. Haug AR, Schmidt GP, Klingenstein A, et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr. 2007; 31: 629-634. (Pubitemid 47457683)
16. Isasi CR, Moadel RM, Blaufox MD., A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005; 90: 105-112. (Pubitemid 40568893)
17. Khatcheressian J, Wolff A, Smith T, et al. American Society of Clinical Oncology 2006: Update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24: 5091-5097. (Pubitemid 46631413)
18. Saad A, Kanate A, Sehbai A, Marano G, Hobbs G, Abraham J., Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. Clin Breast Cancer. 2008; 8: 357-361.
19. Schneider E., Multi-marker testing for cancer: what can we learn from modern prenatal testing for trisomy-21. Cancer Informatics. 2006; 2: 44-47. (Pubitemid 43854388)
20. Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET/CT imaging on the decision making in biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008; 108: 160-165. (Pubitemid 350299439)
21. Aide N, Huchet V, Switsers O, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun. 2007; 28: 267-272. (Pubitemid 46673203)
22. Dirisamer A, Halpern BS, Flory D, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol. 2010; 73: 294-299.
23. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002; 29: 1317-1323. (Pubitemid 44392212)
24. Avril N, Rose C, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000; 18: 3495-3502.
25. Aliaga A, Rousseau J, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2- [F-18]fluoro-d-glucose in murine models of breast cancer. Mol Imaging Biol. 2007; 9: 144-150. (Pubitemid 46705708)
26. Zervoudis S, Peitsidis P, Iatrakis G, et al. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON. 2007; 12: 487-492.
27. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N., Triple-negative breast cancerâcurrent status and future directions. Ann Oncol. 2009; 20: 1913-1927.
28. Molina R, Jo J, Filella X, et al. C-erbB-2, CEA and CA 15-3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999; 19: 2551-2555. (Pubitemid 29392411)
29. Nishimura R, Nagao K, Miyayama H, et al. Elevated serum CA 15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer. 2003; 10: 220-227.
30. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I., Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16: 3375-3379. (Pubitemid 28481635)
31. Du Y, Cullum I, Illidge T, Ell P., Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007; 25: 3440-3447. (Pubitemid 47310881)
32. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N., Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008; 33: 97-101.
33. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol. 2008; 65: 47-58.
34. Aukema T, Rutgers E, Vogel W, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur J Surg Oncol. 2010; 36: 387-392.
35. The GIVIO investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA. 1994; 271: 1587-1592.
36. Rosselini Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trialâNational Research Council Project on Breast Cancer Follow-up. JAMA. 1994; 271: 1593-1597. (Pubitemid 24155619)
37. Joseph E, Hyacinthe M, Lyman G, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol. 1998; 5: 522-528. (Pubitemid 28421752)